Warning: This security is no longer trading.
defunct
Neon Therapeutics, Inc. (NTGN): Price and Financial Metrics
NTGN Price/Volume Stats
| Current price | $3.07 | 52-week high | $6.25 |
| Prev. close | $2.84 | 52-week low | $0.88 |
| Day low | $2.92 | Volume | 3,609,700 |
| Day high | $3.09 | Avg. volume | 516,108 |
| 50-day MA | $2.26 | Dividend yield | N/A |
| 200-day MA | $2.00 | Market Cap | 88.93M |
NTGN Stock Price Chart Interactive Chart >
Neon Therapeutics, Inc. (NTGN) Company Bio
Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is based in Cambridge, Massachusetts.
NTGN Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | 120.86% |
| YTD | N/A |
| 2023 | N/A |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | 0.00% |
| 2019 | -76.54% |
Loading social stream, please wait...